Novo Nordisk Files 14 New Lawsuits Over Compounded Semaglutide

Who is Involved This Time?

Novo Nordisk just dropped another wave of lawsuits—14 new companies hit, bringing their total to 132 lawsuits across 40 states.

And I said it this morning on the podcast... something was coming.

The timing? Not subtle. These lawsuits landed one day after Noom announced discounted compounded semaglutide, joining a market already dominated by Hims and Hers.

But Hims, the largest player in compounded semaglutide? Couriously absent from this list.

Here’s who did get sued:

• Mochi Health (already in an ongoing legal battle with Eli Lilly)

• Fella and Delilah

• Prism Aesthetics

• Zealthy

• Forever Weight Loss

• Renew Weight Loss Med Spa

• Get Relief Rx

• Gorin Plastic Surgery Investments

• Plastic Surgery Associates

• Link Pharmacy

• Axtells Rite Value Pharmacy

• Texas Star Pharmacy

• Bhaumik Diversified

This round continues the pattern: going after smaller players, many of them local med spas, aesthetic clinics, or independent pharmacies.

A post shared by @manonthemounjaro

This doesn’t feel like a pure patent defense strategy.

It feels like Novo Nordisk protecting its moat.

Important context:

We haven’t done a full legal deep dive into each of these new cases yet, this is a fast developing story, and we’re still sorting out what claims are being made.

But at a high level, Novo says these companies are misleading patients into thinking their compounded versions are FDA approved or equally safe.

To be clear, there may be valid safety concerns with some compounders. But for many patients, these meds were the only affordable path forward while branded options were either out of stock or financially impossible.

The Real Fight

This is less about patents and more about power.

Who gets to help patients.Who gets to profit.

Who gets to stay in the room.

Subscribe

Share this if you’ve ever been priced out, denied coverage, or told to wait your turn for a medication that changed your life.

We’ll keep tracking this story at OnThePen.com. The lawsuits are piling up—but so is the resistance.